SUBSCRIBE
SUBSCRIBE

Phase I

Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate
The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.
May 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CanSino Publishes Phase I Data for COVID-19 Vaccine Candidate, Moves into Phase II
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 22, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biotech Bay Companies Fighting Against COVID-19
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
May 22, 2020
 · 
11 min read
 · 
Chelsea Weidman Burke, M.S.
BioForest
Clinical Catch-Up: May 18-22
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
May 22, 2020
 · 
9 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
May 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
New researches on probable cure for HIV approachin
Drug Development
ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials
To learn more about ImmunityBio’s HIV drug candidate, BioSpace spoke to Dr. Whitney and Jeffrey Safrit, PhD, director of Cell-Mediated Therapies in Virology at NantKwest.
May 21, 2020
 · 
9 min read
 · 
Chelsea Weidman Burke
Policy
Biopharma Update on the Novel Coronavirus: May 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
May 21, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 5, 2024
 · 
8 min read
Drug Development
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
March 5, 2024
 · 
3 min read
Drug Development
Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency
March 5, 2024
 · 
2 min read
Drug Development
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
March 5, 2024
 · 
7 min read
Drug Development
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
March 5, 2024
 · 
6 min read
Drug Development
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
March 5, 2024
 · 
7 min read
Drug Development
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors
March 5, 2024
 · 
3 min read
Drug Development
Elysium Therapeutics Announces Compelling Human Proof-of-Concept Data for its SMART™ Opioid, O2P™ Hydrocodone Prodrug for Acute Pain that Could Disrupt the Industry by Establishing New Standards for Opioid Safety
March 5, 2024
 · 
7 min read
Drug Development
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
March 5, 2024
 · 
6 min read
Drug Development
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
March 5, 2024
 · 
2 min read
Drug Development
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
March 5, 2024
 · 
10 min read
Drug Development
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
March 5, 2024
 · 
7 min read
Drug Development
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
March 5, 2024
 · 
3 min read
Drug Development
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
March 4, 2024
 · 
7 min read
Drug Development
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
March 4, 2024
 · 
5 min read
Drug Development
Molecular Templates, Inc. Provides Interim Update
March 4, 2024
 · 
9 min read
Drug Development
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
March 4, 2024
 · 
5 min read
Drug Development
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
March 4, 2024
 · 
9 min read
Drug Development
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
March 4, 2024
 · 
7 min read
Drug Development
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
March 1, 2024
 · 
5 min read
Load More